BIAF vs ITOC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.
ITOC presents a high-risk profile characterized by a Piotroski F-Score of 4/9, indicating only marginal stability amidst a catastrophic price collapse. While the company shows strong top-line revenue growth (91.60%) and exceptional short-term liquidity (Current Ratio 8.83), these are completely overshadowed by an unsustainable operating margin of -681.94%. The stock has plummeted from a 52-week high of $32.00 to $0.28, reflecting a total loss of investor confidence and a severe technical breakdown.
Compare Another Pair
Related Comparisons
BIAF vs ITOC: Head-to-Head Comparison
This page compares bioAffinity Technologies, Inc. (BIAF) and iTonic Holdings Ltd. (ITOC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.